Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients

Glioblastoma is a highly aggressive type of brain tumor for which there is no curative treatment available. Immunotherapies have shown limited responses in unselected patients, and there is an urgent need to identify mechanisms of treatment resistance to design novel therapy strategies.